Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJul 25, 2026
DataAggregated Company Financials
Companies182
  • 7D-0.7%
  • 3M14.7%
  • 1Y10.2%
  • YTD15.0%

Over the last 7 days, the Pharma industry has remained flat, although notably Torrent Pharmaceuticals gained 4.1%. The past year has been better, since the industry has gained 10% in that time. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 25 Jul 2026₹23.7t₹4.5t₹629.3b29.3x37.6x5.3x
Mon, 22 Jun 2026₹22.5t₹4.5t₹643.1b29.1x35x5x
Wed, 20 May 2026₹22.3t₹4.4t₹615.0b29.8x36.3x5.1x
Fri, 17 Apr 2026₹20.4t₹4.3t₹621.0b27.7x32.9x4.7x
Sun, 15 Mar 2026₹20.3t₹4.3t₹621.2b25.1x32.7x4.7x
Tue, 10 Feb 2026₹20.1t₹4.3t₹616.1b27.5x32.7x4.7x
Thu, 08 Jan 2026₹20.9t₹4.2t₹613.3b29x34.1x4.9x
Sat, 06 Dec 2025₹20.6t₹4.2t₹612.9b29x33.6x4.9x
Mon, 03 Nov 2025₹20.2t₹4.1t₹594.9b29.9x33.9x4.9x
Wed, 01 Oct 2025₹19.8t₹4.1t₹588.1b29.9x33.6x4.9x
Fri, 29 Aug 2025₹20.0t₹4.1t₹589.1b29.4x33.9x4.9x
Sun, 27 Jul 2025₹20.9t₹4.0t₹596.9b32.8x35x5.2x
Tue, 24 Jun 2025₹19.9t₹4.0t₹595.3b31.5x33.4x5x
Thu, 22 May 2025₹19.9t₹4.0t₹582.9b32.1x34.1x5x
Sat, 19 Apr 2025₹19.5t₹3.9t₹559.2b28.5x34.8x5x
Mon, 17 Mar 2025₹18.5t₹3.9t₹559.4b27x33.2x4.8x
Wed, 12 Feb 2025₹19.3t₹3.9t₹548.1b30.4x35.2x5x
Fri, 10 Jan 2025₹21.0t₹3.8t₹527.0b33.9x39.8x5.5x
Sun, 08 Dec 2024₹20.8t₹3.8t₹526.7b36x39.5x5.5x
Tue, 05 Nov 2024₹21.1t₹3.8t₹504.9b37.6x41.7x5.6x
Thu, 03 Oct 2024₹21.6t₹3.7t₹492.6b41.6x43.8x5.8x
Sat, 31 Aug 2024₹21.2t₹3.7t₹492.4b39.8x43x5.7x
Mon, 29 Jul 2024₹19.5t₹3.7t₹459.9b36.7x42.4x5.3x
Wed, 26 Jun 2024₹17.4t₹3.6t₹448.3b33.2x38.9x4.9x
Fri, 24 May 2024₹17.2t₹3.5t₹453.6b34x37.9x4.8x
Sun, 21 Apr 2024₹16.6t₹3.5t₹418.9b33.2x39.6x4.8x
Tue, 19 Mar 2024₹16.7t₹3.5t₹418.7b32.1x39.9x4.8x
Thu, 15 Feb 2024₹16.7t₹3.5t₹425.0b33.9x39.2x4.8x
Sat, 13 Jan 2024₹15.7t₹3.4t₹395.3b35.2x39.6x4.6x
Mon, 11 Dec 2023₹14.3t₹3.4t₹395.1b31.4x36.1x4.2x
Wed, 08 Nov 2023₹13.4t₹3.3t₹378.4b30.1x35.4x4x
Fri, 06 Oct 2023₹13.3t₹3.3t₹369.5b30x35.9x4.1x
Sun, 03 Sep 2023₹12.8t₹3.3t₹367.0b29.3x34.9x3.9x
Tue, 01 Aug 2023₹12.8t₹3.2t₹345.7b28.2x36.9x4x
Price to Earnings Ratio

36.9x


Total Market Cap: ₹12.8tTotal Earnings: ₹345.7bTotal Revenue: ₹3.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.6x.
  • The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 22% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market-1.36%
Healthcare-0.67%
Pharma-0.72%
Pharma-0.72%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
500420 Torrent Pharmaceuticals₹4.96k4.1%
+₹273.3b		37.7%PE87.2x
LAURUSLABS Laurus Labs₹1.60k4.7%
+₹38.5b		91.1%PE97.3x
SUNPHARMA Sun Pharmaceutical Industries₹1.94k0.4%
+₹20.4b		14.2%PE40.6x
EMCURE Emcure Pharmaceuticals₹1.88k5.5%
+₹18.5b		33.6%PE38.6x
RUBICON Rubicon Research₹1.52k5.6%
+₹13.3b		n/aPE101.5x

Latest News

GLAND
₹2,379.80
Gland Pharma
7D
-2.8%
1Y
17.9%
500124
₹1,152.60
Dr. Reddy's Laboratories
7D
-4.8%
1Y
-9.8%
Narrative Update • Jul 23

500124: New Biologics And Diabetes Launches Will Drive Future Upside

Analysts have trimmed their price target on Dr. Reddy's Laboratories from ₹1,679 to about ₹1,600, citing updated assumptions that combine slightly higher projected revenue growth and profit margins with a lower future P/E multiple. What's in the News Dr. Reddy's Laboratories reported that the USFDA completed a Pre License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad, issuing a Form 483 with seven observations that the company plans to address within the required timeline.
500257
₹2,369.45
Lupin
7D
-3.0%
1Y
21.5%
ZYDUSLIFE
₹1,108.70
Zydus Lifesciences
7D
-3.1%
1Y
13.5%
New Narrative • Jul 22

Specialty Therapies And Biosimilars Expansion Will Likely Pressure Margins And Earnings

Catalysts About Zydus Lifesciences Zydus Lifesciences is a diversified pharmaceutical and healthcare company with operations across generics, specialty medicines, biosimilars, consumer wellness and medical devices. What are the underlying business or industry changes driving this perspective?
532482
₹833.65
Granules India
7D
-5.3%
1Y
77.9%
Narrative Update • Jul 22

532482: Sole FTF Complex Generics Will Drive Future Margins And Fair Value

Analysts have raised their price target for Granules India from ₹931 to ₹1,110, reflecting updated assumptions for revenue growth, profit margins and future P/E expectations. What’s in the News for Granules India Granules India has scheduled a board meeting on July 21, 2026 to consider and approve its unaudited financial results for the first quarter ended June 30, 2026.
ACUTAAS
₹3,259.50
Acutaas Chemicals
7D
-9.9%
1Y
181.4%
Narrative Update • Jul 22

ACUTAAS: Higher Profitability Outlook And Dividend Plan Will Shape A Measured Future

The analyst price target for Acutaas Chemicals has been raised from ₹2,290 to ₹3,772 as analysts factor in updated assumptions for revenue growth, profit margins and future P/E expectations. What’s in the News for Acutaas Chemicals A board meeting is scheduled on Jul 24, 2026 to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended Jun 30, 2026.
EMCURE
₹1,881.00
Emcure Pharmaceuticals
7D
5.5%
1Y
33.6%
ALKEM
₹5,633.50
Alkem Laboratories
7D
1.3%
1Y
12.4%
RUBICON
₹1,520.20
Rubicon Research
7D
5.6%
1Y
n/a
500660
₹2,513.25
GlaxoSmithKline Pharmaceuticals
7D
2.4%
1Y
-20.3%
IPCALAB
₹1,762.70
Ipca Laboratories
7D
-7.3%
1Y
16.8%
Narrative Update • Jul 17

IPCALAB: Board Reviews And Merger Plan Will Shape Measured Upside Potential

The analyst price target for Ipca Laboratories has shifted from ₹1,887 to about ₹1,968, with analysts linking this change to updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Ipca Laboratories has scheduled a board meeting on May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a dividend recommendation for the 2025-26 financial year.
LAURUSLABS
₹1,601.20
Laurus Labs
7D
4.7%
1Y
91.1%
Narrative Update • Jul 17

LAURUSLABS: Lower Future P/E Assumptions Will Continue To Restrain Margin Upside

Analysts now see Laurus Labs' fair value at about ₹540.50, down from roughly ₹606.49. This reflects updated assumptions on future P/E levels as well as refreshed revenue growth and margin estimates.
MANKIND
₹2,507.20
Mankind Pharma
7D
0.9%
1Y
-3.7%
500420
₹4,959.80
Torrent Pharmaceuticals
7D
4.1%
1Y
37.7%
GLENMARK
₹2,192.00
Glenmark Pharmaceuticals
7D
-1.9%
1Y
2.2%
SUNPHARMA
₹1,941.10
Sun Pharmaceutical Industries
7D
0.4%
1Y
14.2%